At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, explains the clinical impact of emerging treatments, including abiraterone acetate and enzalutamide in both post-chemotherapy and pre-chemotherapy settings, on the care and quality of life of patients with metastatic castration-resistant prostate cancer.
Quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
4th February 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?